ArticleNPJ breast cancer2025
Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Scalp cooling is commonly used to reduce chemotherapy-induced alopecia (CIA) and has been suggested to aid hair regrowth after treatment. However, a subset of patients still experience persistent CIA (PCIA) despite undergoing scalp cooling. In this post hoc analysis of two prospective trials, we investigated clinical and genetic factors associated with PCIA among 123 women with stage I-III breast cancer treated with anthracycline- and/or taxane-based chemotherapy and scalp cooling. PCIA, defined as incomplete hair regrowth at 6 months post-chemotherapy, was observed in 12% of patients. Tamoxifen monotherapy was identified as a strong independent risk factor (adjusted odds ratio, 11.66; 95% CI, 1.87-120.20), while variants in chr20p11 and HLA-DQB1 showed non-significant trends. Hair thickness remained significantly lower in the tamoxifen monotherapy. These findings suggest that tamoxifen may impair follicular recovery after chemotherapy, highlighting the importance of individualized counseling and close dermatologic follow-up in patients undergoing scalp cooling.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.